UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 6, 2012, Pages 647-662

  Ramachandran, P ^a   Fraser, A ^a   Agarwal, K ^b   Austin, A ^c   Brown, A ^d   Foster, G R ^e   Fox, R ^f   Hayes, P C ^g   Leen, C ^h   Mills, P R ^f   Mutimer, D J ⁱ   Ryder, S D ^j   Dillon, J F ^k  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ROYAL DERBY HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j QUEEN S MEDICAL CENTRE   (United Kingdom)

^k UNIVERSITY OF DUNDEE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BOCEPREVIR; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; STEROID; TELAPREVIR; VIRUS RNA;

ALGORITHM; ANEMIA; ANORECTAL DISEASE; ARTICLE; BLOOD TRANSFUSION; COMORBIDITY; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; GENOTYPE; HEALTH CARE PERSONNEL; HEMORRHOID; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER FIBROSIS; MEDICAL PRACTICE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; VIRUS LOAD; VIRUS RESISTANCE;

ALGORITHMS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; PATIENT SELECTION; POLYETHYLENE GLYCOLS; PROLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; VIRAL LOAD;

EID: 84857368831     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.04992.x     Document Type: Article

References (50)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 74-81.
2. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
3. Alter HJ, Seeff LB,. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
4. Camma C, Giunta M, Andreone P, Craxi A,. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
5. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
6. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
7. European Association for the Study of the Liver,. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
8. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
9. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
11. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al,. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.
12. Poynard T, Colombo M, Bruix J, et al,. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28.
13. Jensen DM, Marcellin P, Freilich B, et al,. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-40.
14. Rosen HR,. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011; 364: 2429-38.
15. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
16. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
17. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
18. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
20. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
21. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
22. Foster GR, Hezode C, Bronowicki JP, et al,. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-9.
23. Mangia A, Mottola L,. Treatment of non-genotype 1 hepatitis C virus patients. Curr Gastroenterol Rep 2012; 14: 87-93.
24. Ferrante SA, Chhatwal J, Elbasha E, et al,. Cost-Effectiveness of Boceprevir Based Regimens in Previously Untreated Adult Subjects with Chronic Hepatitis C Genotype 1. San Francisco: AASLD, 2011.
25. Chhatwal J, Ferrante SA, Dasbach EJ, et al,. Cost-effectiveness of Boceprevir Use in Patients with Chronic Hepatitis C Genotype-1 Who Failed Prior Treatment with Peginterferon/Ribavirin. San Francisco: AASLD, 2011.
26. Gellad ZF, Naggie S, Reed SD, et al,. The Cost-Effectiveness of a Telaprevir-Inclusive Regimen as Initial Therapy for Genotype 1 Hepatitis C Infection in Individuals with the CC IL-28B Polymorphism. San Francisco: AASLD, 2011.
27. Kau A, Vermehren J, Sarrazin C,. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-51.
28. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
29. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
30. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
31. Kurosaki M, Tanaka Y, Nishida N, et al,. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-48.
32. Jafferbhoy H, Miller MH, El Wahed Z, Dillon JF,. Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR. J Hepatol 2011; 55: 1162-4.
33. Poordad FF,. Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther 2010; 31: 1251-67.
34. Zeuzem S, Foster GR, Andreone P, et al,. Different likelihood of achieving svr on a telaprevir-containing regimen among null responders, partial responders and relapsers irrespective of similar responses after a peginterferon/ribavirin 4-week lead-in phase: realize study subanalysis. Hepatology 2011; 54: 986A-7.
35. Welsch C, Domingues FS, Susser S, et al,. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 2008; 9: R16.
36. Susser S, Welsch C, Wang Y, et al,. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-18.
37. Forestier N, Reesink HW, Weegink CJ, et al,. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-8.
38. Kieffer TL, Sarrazin C, Miller JS, et al,. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-9.
39. Vierling JM, Ralston R, Lawitz EJ, et al,. Long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin (P/R) in patients with chronic hepatitis c, genotype 1 (Chc-G1). J Hepatol 2010; 52: S470-1.
40. Zeuzem S, Sulkowski MS, Zoulim F, et al,. Long-term follow-up of patients with chronic hepatitis c treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the extend study. Hepatology 2010; 52: S436A.
41. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
42. Roberts SK, Andreone P, Pol S, et al,. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. Hepatology 2011; 54: 1007A-8.
43. Naeger LK, Harrington PR,. Effect of On-Treatment Undetectable or Detectable/BLOQ HCV RNA MEasurements on SVR Rates in Phase 3 Clinical Trials of Boceprevir and Telaprevir. In: 6th International Workshop on Hepatitis C-Resistance and New Compounds; 2011 24/06/2011; Cambridge, USA; 2011.
44. Goldberg D, Brown G, Hutchinson S, et al,. Hepatitis C action plan for Scotland: phase II (May 2008-March 2011). Euro Surveill 2008; 13: 211-2.
45. Marcellin P, Forns X, Goeser T, et al,. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-68.
46. Flamm SL, Lawitz EJ, Jacobson IM, et al,. High sustained virologic response (SVR) among genotype i previous Non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2A/ribavirin. Gastroenterology 2011; 140: S145.
47. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S,. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.
48. Chayama K, Takahashi S, Toyota J, et al,. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 2011 [Epub ahead of print].
49. Zeuzem S, Asselah T, Angus P, et al,. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-55.
50. Gane EJ, Roberts SK, Stedman CA, et al,. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-75.